Key result
Early clopidogrel discontinuation precedes very late bare-metal stent thrombosis despite adjacent drug-eluting stent patency.
Why the study?
Very late stent thrombosis of bare metal stents with concurrent patency of drug eluting stents in the same vessel is not well characterized.
This case report describes an unusual presentation of very late bare metal stent thrombosis with a patent drug-eluting stent in the same vessel following clopidogrel discontinuation.
Answers are grounded in this paper and cite their sources.
Highlights very late BMS thrombosis risk after clopidogrel cessation; hypothesis-generating for differential thrombosis susceptibility versus concurrent DES.
We report a case of very late stent thrombosis of a bare metal stent with a concurrent drug eluting stent's patency in the same coronary vessel, in a patient undergoing primary angioplasty who discontinued his clopidogrel regimen a few weeks after successful deployment of the stents.
No takes yet. Share an insight, caveat, or question.
Tanzilli et al. (2009) studied this question. Early clopidogrel discontinuation preceded very late thrombosis of a bare metal stent, while a concurrent drug-eluting stent in the same coronary vessel remained patent.
Synapse has enriched 10 related papers. Consider them for comparative context: